Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
14°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
November 12, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 12, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
November 11, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
November 11, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
November 07, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 05, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 22, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
August 28, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 07, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
July 29, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
July 23, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
July 01, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
May 02, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
April 18, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
March 04, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
February 29, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
February 27, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
February 22, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 08, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
December 05, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
December 04, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 29, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
November 27, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.